Post by Ampersand Biomedicines

We are excited to announce that we have entered into a collaboration with the globally recognized gene therapy expert Genethon to engineer gene therapies with superior tissue specificity. By combining our precision targeting capabilities with Genethon’s expertise in AAV engineering, the partnership aims to advance more effective and better tolerated therapies for patients. This collaboration leverages our AND™ Platform, which has discovered exquisitely selective ligands for specific cells across every major tissue and cell type in the human body to support a new level of precision in therapeutic targeting. Read more: https://lnkd.in/ezSS77N5